Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact

被引：0

作者：

Diaz-Guardamino, I. Echavarria ^{[1
]}

Lopez-Tarruella Cobo, S. ^{[2
]}

Del Monte-Millan, M. ^{[2
]}

Alvarez, E. ^{[2
]}

Jerez Gilarranz, Y. ^{[2
]}

Moreno Anton, F. ^{[3
]}

Garcia Saenz, J. A. ^{[4
]}

Massarrah, T. ^{[1
]}

Ocana, I. ^{[5
]}

Cebollero, M. ^{[6
]}

Ballesteros Garcia, A. I. ^{[7
]}

Bohn Sarmiento, U. ^{[8
]}

Gomez, H. ^{[9
]}

Fuentes Rivera, H. ^{[10
]}

Herrero Lopez, B. ^{[11
]}

Polo, C. ^{[12
]}

Bueno, O. ^{[13
]}

Rahimi, P. ^{[5
]}

Bueno Muino, C. ^{[14
]}

Martin Jimenez, M. ^{[15
]}

机构：

[1] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Inst Invest Sanitaria Gregorio Maranon, CiberOnc, Madrid, Spain

[2] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, CIBERONC ISCIII, GEICAM,Spanish Breast Canc Grp, Madrid, Spain

[3] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[4] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, CIBERONC, Med Oncol Dept, Madrid, Spain

[5] Inst Invest Sanitaria GregorioMaranon, Dept Med Oncol, Madrid, Spain

[6] Hosp Gen Univ Gregorio Maranon, Pathol, Madrid, Spain

[7] Hosp Univ Princesa, Dept Med Oncol, Madrid, Spain

[8] Hosp Univ Gran Canaria Doctor Negrin, Dept Med Oncol, Las Palmas Gran Canaria, Canary Island, Spain

[9] Oncosalud SAC, Radioncol Dept, Lima, Peru

[10] Aliada Canc, Ctr Oncol, Dept Med Oncol, Lima, Peru

[11] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[12] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[13] Hosp Gen Univ Gregorio Maranon, Radiol, Madrid, Spain

[14] Hosp Sur, Med Oncol, Madrid, Spain

[15] Hosp Gen Univ Gregorio Maranon, Med Dept, Serv Oncol, Madrid, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

261P

引用

页码：S324 / S325

页数：2

共 50 条

[41] Platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
Poggio, Francesca
Bruzzone, Marco
Ceppi, Marcello
Ponde, Noam Falbel
La Valle, Giovanni
Sotiriou, Christos
Del Mastro, Lucia
De Azambuja, Evandro
Lambertini, Matteo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Response to Neoadjuvant Chemotherapy of Triple Negative Breast Cancer
Tokudome, N.
Ito, Y.
Takahashi, S.
Sugihara, T.
Hosonaga, M.
Iwasaki, R.
Hattori, M.
Fukuda, T.
Mitsuhashi, K.
Kobayashi, K.
Taira, S.
Saito, Y.
Fukada, I
Ueki, N.
Tsutsumi, C.
Miyagi, Y.
Iwase, T.
Osako, T.
Horii, R.
Akiyama, F.
Hatake, K.
CANCER RESEARCH, 2009, 69 (24) : 571S - 572S
[43] Germline (g)BRCA1/2 mutations (m) and hematological toxicities in patients (pts) with triple negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NACT)
Furlanetto, Jenny
Mobus, Volker
Schneeweiss, Andreas
Rhiem, Kerstin
Tesch, Hans
Blohmer, Jens-Uwe
Lubbe, Kristina
Untch, Michael
Salat, Christoph
Huober, Jens
Klare, Peter
Schmutzler, Rita
Couch, Fergus J.
Lederer, Bianca
Gerber, Bernd
Zahm, Dirk-Michael
Bauerfeind, Ingo
Nekljudova, Valentina
Hanusch, Claus
Jackisch, Christian
Link, Theresa
Loibl, Sibylle
Fasching, Peter A.
CANCER RESEARCH, 2020, 80 (04)
[44] Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Shimanuki, Yumiko
Shimomura, Akihiko
Yoshimura, Kenichi
Terakado, Hiroyuki
Shimizu, Chikako
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3521 - +
[45] Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC)
Neciosup, S. P.
Ventura, L.
Gomez, H.
Pinto, J. A.
Marcelo, M. J.
Vidaurre, T.
Vallejos Sologuren, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[46] Breast cancer, neoadjuvant chemotherapy and residual disease
Mariana Chávez-MacGregor
Ana María González-Angulo
Clinical and Translational Oncology, 2010, 12 : 461 - 467
[47] Breast cancer, neoadjuvant chemotherapy and residual disease
Chavez-MacGregor, Mariana
Gonzalez-Angulo, Ana Maria
CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (07): : 461 - 467
[48] Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC)
Lee, S.
Park, Y. H.
Cho, E. Y.
Ham, Y. H.
Seo, J. J.
Ahn, J. S.
Im, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[49] Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
Ryan, P. D.
Tung, N. M.
Isakoff, S. J.
Golshan, M.
Richardson, A.
Corben, A. D.
Smith, B. L.
Gelman, R.
Winer, E. P.
Garber, J. E.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[50] Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC)
Echavarria Diaz-Guardamino, I.
Lopez-Tarruella, S.
Garcia-Saenz, J. A.
Gomez Moreno, H.
Moreno, F.
Jerez, Y.
Fuentes, H.
Marquez-Rodas, I.
Cebollero, M.
Del Monte-Millan, M.
Picornell, A.
Massarrah, T.
Barnadas, A.
Prat, A.
Ballesteros Garcia, A.
Colomer Bosch, R.
Pelaez, B.
Gonzalez-Rivera, M.
Perou, C. M.
Martin, M.
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →